Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
This study investigated the clinical long-term effect of incobotulinumtoxinA (incoBoNT/A) in 33 cervical dystonia (CD) patients who had developed partial secondary therapy failure (PSTF) under previous long-term botulinum toxin (BoNT) treatment. Patients were treated four times every 12 weeks with i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.636590/full |
| _version_ | 1818416654524088320 |
|---|---|
| author | Harald Hefter Christian J. Hartmann Ulrike Kahlen Sara Samadzadeh Dietmar Rosenthal Marek Moll |
| author_facet | Harald Hefter Christian J. Hartmann Ulrike Kahlen Sara Samadzadeh Dietmar Rosenthal Marek Moll |
| author_sort | Harald Hefter |
| collection | DOAJ |
| description | This study investigated the clinical long-term effect of incobotulinumtoxinA (incoBoNT/A) in 33 cervical dystonia (CD) patients who had developed partial secondary therapy failure (PSTF) under previous long-term botulinum toxin (BoNT) treatment. Patients were treated four times every 12 weeks with incoBoNT/A injections. Physicians assessed treatment efficacy using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) at the baseline visit, week 12 and 48. Patients rated quality of life of CD with the Craniocervical Dystonia Questionnaire (CDQ-24). Titres of neutralizing antibodies(NAB) were determined at start of the study and after 48 weeks. All patients had experienced significant and progressive worsening of symptoms in the last 6 months of previous BoNT treatment. Repeated incoBoNT/A injections resulted in a significant reduction in mean TWSTRS at week 12 and 48. Patients' rating of quality of life was highly correlated with TWSTRS but did not change significantly over 48 weeks. During the 48 weeks -period of incoBoNT/A treatment NAB titres decreased in 32.2%, did not change in 45.2%, and only increased in 22.6% of the patients. Thus, repeated treatment with the low dose of 200 MU incoBoNT/A over 48 weeks provided a beneficial clinical long-term effect in PSTF and did not booster titres of NAB. |
| first_indexed | 2024-12-14T11:54:19Z |
| format | Article |
| id | doaj.art-4a400d0c4b5c46df9219b54ecf44f920 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-14T11:54:19Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-4a400d0c4b5c46df9219b54ecf44f9202022-12-21T23:02:11ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-02-011210.3389/fneur.2021.636590636590Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing ProteinsHarald HefterChristian J. HartmannUlrike KahlenSara SamadzadehDietmar RosenthalMarek MollThis study investigated the clinical long-term effect of incobotulinumtoxinA (incoBoNT/A) in 33 cervical dystonia (CD) patients who had developed partial secondary therapy failure (PSTF) under previous long-term botulinum toxin (BoNT) treatment. Patients were treated four times every 12 weeks with incoBoNT/A injections. Physicians assessed treatment efficacy using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) at the baseline visit, week 12 and 48. Patients rated quality of life of CD with the Craniocervical Dystonia Questionnaire (CDQ-24). Titres of neutralizing antibodies(NAB) were determined at start of the study and after 48 weeks. All patients had experienced significant and progressive worsening of symptoms in the last 6 months of previous BoNT treatment. Repeated incoBoNT/A injections resulted in a significant reduction in mean TWSTRS at week 12 and 48. Patients' rating of quality of life was highly correlated with TWSTRS but did not change significantly over 48 weeks. During the 48 weeks -period of incoBoNT/A treatment NAB titres decreased in 32.2%, did not change in 45.2%, and only increased in 22.6% of the patients. Thus, repeated treatment with the low dose of 200 MU incoBoNT/A over 48 weeks provided a beneficial clinical long-term effect in PSTF and did not booster titres of NAB.https://www.frontiersin.org/articles/10.3389/fneur.2021.636590/fullincobotulinumtoxinAcervical dystoniacomplexing proteinspartial secondary therapy failureneutralizing antibodies |
| spellingShingle | Harald Hefter Christian J. Hartmann Ulrike Kahlen Sara Samadzadeh Dietmar Rosenthal Marek Moll Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins Frontiers in Neurology incobotulinumtoxinA cervical dystonia complexing proteins partial secondary therapy failure neutralizing antibodies |
| title | Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins |
| title_full | Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins |
| title_fullStr | Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins |
| title_full_unstemmed | Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins |
| title_short | Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins |
| title_sort | clinical improvement after treatment with incobotulinumtoxina xeomin r in patients with cervical dystonia resistant to botulinum toxin preparations containing complexing proteins |
| topic | incobotulinumtoxinA cervical dystonia complexing proteins partial secondary therapy failure neutralizing antibodies |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2021.636590/full |
| work_keys_str_mv | AT haraldhefter clinicalimprovementaftertreatmentwithincobotulinumtoxinaxeomininpatientswithcervicaldystoniaresistanttobotulinumtoxinpreparationscontainingcomplexingproteins AT christianjhartmann clinicalimprovementaftertreatmentwithincobotulinumtoxinaxeomininpatientswithcervicaldystoniaresistanttobotulinumtoxinpreparationscontainingcomplexingproteins AT ulrikekahlen clinicalimprovementaftertreatmentwithincobotulinumtoxinaxeomininpatientswithcervicaldystoniaresistanttobotulinumtoxinpreparationscontainingcomplexingproteins AT sarasamadzadeh clinicalimprovementaftertreatmentwithincobotulinumtoxinaxeomininpatientswithcervicaldystoniaresistanttobotulinumtoxinpreparationscontainingcomplexingproteins AT dietmarrosenthal clinicalimprovementaftertreatmentwithincobotulinumtoxinaxeomininpatientswithcervicaldystoniaresistanttobotulinumtoxinpreparationscontainingcomplexingproteins AT marekmoll clinicalimprovementaftertreatmentwithincobotulinumtoxinaxeomininpatientswithcervicaldystoniaresistanttobotulinumtoxinpreparationscontainingcomplexingproteins |